目的:观察缬沙坦联合红花黄色素钠治疗糖尿病肾病蛋白尿患者的临床疗效及安全性。方法:选取90例糖尿病肾病蛋白尿患者作为研究对象,随机分为观察组和对照组各45例。对照组患者给予口服缬沙坦胶囊(80mg/次,1次/天)治疗;观察组患者在口服缬沙坦胶囊基础上,静滴中药制剂红花黄色素氯化钠注射液(100mL/次,1次/天),4周为1个疗程,2个疗程后比较两组患者疗效,并比较治疗前后24h尿微量白蛋白(UAE)。结果:观察组患者总有效率为91.1%,明显优于对照组的77.7%,差异具有统计学意义(P<0.05);治疗后,两组患者UAE较治疗前均下降,且观察组优于对照组,差异具有统计学意义(P<0.05)。两组患者均未出现明显不良反应。结论:缬沙坦胶囊合红花黄色素钠治疗DN蛋白尿临床疗效显著,可有效减少微量白蛋白尿,安全性较高,值得临床推广应用。 Objective: To observe the clinical efficacy and safety of valsartan combined with safflower sodium in the treatment of diabetic nephropathy proteinuria. Methods: Ninety patients with diabetic nephropathy and proteinuria were randomly divided into observation group (45 cases) and control group (45 cases). The patients in the control group were given oral valsartan capsules (80mg / time, once a day). The patients in the observation group were treated with valsartan capsules intravenously. The rats in the observation group were given intravenous safflower yellow sodium chloride injection (100mL / time , Once a day), 4 weeks for a course of treatment, after two courses of treatment were compared between two groups, and 24h urine microalbuminuria (UAE) before and after treatment. Results: The total effective rate of the observation group was 91.1%, which was significantly better than that of the control group (77.7%), the difference was statistically significant (P <0.05); after treatment, the UAE of both groups decreased compared with that before treatment, Control group, the difference was statistically significant (P <0.05). No significant adverse reactions occurred in both groups. Conclusion: Valsartan capsule safflower yellow sodium in the treatment of DN proteinuria clinical significant effect, which can effectively reduce microalbuminuria, high safety, worthy of clinical application.